A new drug for a type of brain cancer, called IDH-mutant low-grade glioma, was approved this month by the U.S. Food and Drug Administration—a promising treatment that stemmed from a genetic discovery made at the Johns Hopkins Cancer Center 16 years ago. The drug, called vorasidenib, is a targeted cancer therapy that works by inhibiting […] The post FDA Approves Drug That Targets Brain Cancer Gene Mutation That Could Delay Need for Radiation and Chemotherapy appeared first on Good News Network.